Co-Diagnostics, Inc.(CODX)

NASDAQ Capital Market

Sector: Healthcare | Industry: Medical - Devices

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Latest News & Analysis

Co-Diagnostics: Global expansion, financial review, and innovation in molecular diagnostics. Strategic moves in India, trade fairs, and future outlook analyzed.

Feb 21, 2025

Co-Diagnostics: Global Expansion, India Facility, and Q3 2024

Co-Diagnostics navigates global expansion and innovation in molecular diagnostics amid financial challenges. A look at recent activities, financials, and market strategies.